Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Posts Higher Q2 Earnings, Sales; Revises 2021 Outlook

07/29/2021 | 07:12am EDT


© MT Newswires 2021
All news about MERCK & CO., INC.
09/18MERCK : KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab ..
BU
09/18MERCK : KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival..
BU
09/17Preview -- Barron's
DJ
09/17MERCK : Receives Positive Opinion for Keytruda, Chemotherapy Combination From Eu..
MT
09/17MERCK : Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combi..
BU
09/17Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (Pembrolizumab) in Comb..
CI
09/17Merck Gets CHMP Backing of Keytruda in Triple-Negative Breast Cancer
DJ
09/17MERCK : EquiTrace wins Best Start-Up Award & new Best Vet Tech Award at the Inno..
AQ
09/16SILVERBACK THERAPEUTICS : Reports Early Data From Phase 1/1b Study of SBT6050 in..
MT
09/16HOOKIPA PHARMA : announces clinical collaboration with Merck & Co., Inc., Kenilw..
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 46 894 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 15,7x
Yield 2021 3,62%
Capitalization 181 B 181 B -
EV / Sales 2021 4,19x
EV / Sales 2022 3,79x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 71,68 $
Average target price 94,61 $
Spread / Average Target 32,0%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-12.37%181 449
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604